---
title: "Huatai Securities Sticks to Their Buy Rating for HUTCHMED (China)  (HCM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294572020.md"
description: "Huatai Securities analyst maintained a Buy rating on HUTCHMED (China) yesterday and set a price target of HK$32.82. The company’s shares closed yesterday at HK$17.71.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Currently, the analyst consensus on HUTCHMED (China) is a Moderate Buy with an average price target of p278.12."
datetime: "2026-08-01T05:05:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294572020.md)
  - [en](https://longbridge.com/en/news/294572020.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294572020.md)
generator: "portal-rs"
---

# Huatai Securities Sticks to Their Buy Rating for HUTCHMED (China)  (HCM)

Huatai Securities analyst maintained a Buy rating on HUTCHMED (China) yesterday and set a price target of HK$32.82. The company’s shares closed yesterday at HK$17.71.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Currently, the analyst consensus on HUTCHMED (China) is a Moderate Buy with an average price target of p278.12.

### Related Stocks

- [HCM.US](https://longbridge.com/en/quote/HCM.US.md)
- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)
- [601688.CN](https://longbridge.com/en/quote/601688.CN.md)
- [06886.HK](https://longbridge.com/en/quote/06886.HK.md)
- [HTSC.UK](https://longbridge.com/en/quote/HTSC.UK.md)

## Related News & Research

- [HUTCHMED says savolitinib plus AstraZeneca’s Tagrisso extends PFS in China Phase III SANOVO lung cancer trial](https://longbridge.com/en/news/297475889.md)
- [AstraZeneca-Hutchmed drug combination shows promise in advanced lung cancer study](https://longbridge.com/en/news/297608177.md)
- [These Were The Best And Worst Performing Assets Of August](https://longbridge.com/en/news/297728245.md)
- [AcuCort notifies availability of August 2026 newsletter press release](https://longbridge.com/en/news/297505730.md)
- [eDreams ODIGEO Beats Market Estimates One Quarter Into Its Peak Investment Year and Further Grows Subscribers to 8.1 Million | EDDRF Stock News](https://longbridge.com/en/news/297623101.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**